Loading...
•
Dec 31, 2023
Sangamo Q4 2023 Earnings Report
Reported business highlights and financial results, including data supporting neurology pipeline advancement.
Key Takeaways
Sangamo Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of its neurology pipeline and progress with novel AAV capsid delivery technology. The company is seeking partnerships for its Fabry disease program and anticipates pivotal data read-out for its Hemophilia A collaboration with Pfizer in mid-2024.
Data from novel proprietary neurotropic AAV delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates.
Chronic neuropathic pain and prion disease preclinical programs advance, with IND and CTA submissions expected in the fourth quarters of 2024 and 2025, respectively.
FDA aligned on an abbreviated pathway to potential approval, and EMA granted PRIME eligibility for isaralgagene civaparvovec in Fabry disease.
Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration by early 2025 if the pivotal readout is supportive.
Sangamo
Sangamo
Forward Guidance
Sangamo expects total operating expenses in the range of approximately $145 million to $165 million in 2024 on a GAAP basis. Non-GAAP total operating expenses, excluding stock-based compensation and depreciation and amortization, are expected to be in the range of approximately $125 million to $145 million in 2024, subject to additional funding.